(Total Views: 614)
Posted On: 03/22/2018 11:38:57 AM
Post# of 103535
$ETBI: NEWS JUST OUT!!
More press releases» | Press Release
EastGate Biotech Announces that It Has Reached a Definitive Settlement Agreement with Northbridge Financial Inc.
The Share Reserve with Transfer Agent has been Canceled and all Remaining Shares have been Returned to EastGate Biotech
WEST CALDWELL, NJ and TORONTO, ON / ACCESSWIRE / March 22, 2018 / EastGate Biotech Corp. (OTC PINK: ETBI), a pharmaceutical company that focuses on innovative technological developments specifically in insulin drug delivery for the treatment of type 2 diabetes, announced today that it has reached a definitive settlement agreement with Northbridge Financial. Last year EastGate entered into a series of 3(a)(10) exemptions with Northbridge Financial detailed in 2 Form 8-K filings. Northbridge Financial released all remaining debt from the Settlement Agreement dated May 9, 2017, between Northbridge Financial Inc. and EastGate Biotech Corp. As a result, Northbridge Financial has released all remaining shares in the reserve with the EastGate's Transfer Agent back to the company.
"We are pleased that we were able to reach a settlement with Northbridge Financial," said Anna Gluskin, CEO of EastGate. "We are committed to pursuing non-dilutive and non-toxic financing and are taking the steps to clear the path to collaborate and engage with other financial opportunities to pursue our development objectives," concluded Gluskin.
http://www.digitaljournal.com/pr/3706098
More press releases» | Press Release
EastGate Biotech Announces that It Has Reached a Definitive Settlement Agreement with Northbridge Financial Inc.
The Share Reserve with Transfer Agent has been Canceled and all Remaining Shares have been Returned to EastGate Biotech
WEST CALDWELL, NJ and TORONTO, ON / ACCESSWIRE / March 22, 2018 / EastGate Biotech Corp. (OTC PINK: ETBI), a pharmaceutical company that focuses on innovative technological developments specifically in insulin drug delivery for the treatment of type 2 diabetes, announced today that it has reached a definitive settlement agreement with Northbridge Financial. Last year EastGate entered into a series of 3(a)(10) exemptions with Northbridge Financial detailed in 2 Form 8-K filings. Northbridge Financial released all remaining debt from the Settlement Agreement dated May 9, 2017, between Northbridge Financial Inc. and EastGate Biotech Corp. As a result, Northbridge Financial has released all remaining shares in the reserve with the EastGate's Transfer Agent back to the company.
"We are pleased that we were able to reach a settlement with Northbridge Financial," said Anna Gluskin, CEO of EastGate. "We are committed to pursuing non-dilutive and non-toxic financing and are taking the steps to clear the path to collaborate and engage with other financial opportunities to pursue our development objectives," concluded Gluskin.
http://www.digitaljournal.com/pr/3706098
(1)
(0)
Sojourner here following God, obeying God, and cleaving to Him. The journey is onward.
Scroll down for more posts ▼
